Combining genome-wide association studies (GWAS) with metabolomics and Mendelian randomization is transforming precision medicine by uncovering causal links between genetic variants and clinical outcomes, rather than just correlations. This approach deepens GWAS insights, helping identify actionable therapeutic targets, yet remains underutilized in research.